
The study aimed to validate an echocardiographic algorithm derived by machine learning (e′VM) and explore whether it can identify subgroups of individuals who benefit from spironolactone. Most participants had either a 'diastolic changes' or 'diastolic changes with structural remodelling' phenotype. Spironolactone significantly reduced certain biomarkers in the 'diastolic changes with structural remodelling' phenotype but not in other phenotypes. The e′VM algorithm may help identify individuals who will benefit from spironolactone.
Like
Save
Share